Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered into a licensing agreement with SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group. SOTIO will gain access to Synaffix’s ADC technologies, GlycoConnect, HydraSpace and toxSYN linker-payloads, in an initial ADC program with the option to expand research and commercial licenses into two additional progr...